Initial clinical evaluation of indigenous90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.

INTRODUCTION The kidneys play an essential role in PRRT. The infusion of amino acids could reduce uptake in the kidney of radiolabelled peptides. The purpose of this study was to determine the extent of kidney damage post PRRT. MATERIAL AND METHODS 53 patients, with disseminated neuroendocrine tumours (NET), received 3-5 cycles of up to a maximum 7.4 GBq/m2 calculated dose of 90Y-DOTATATE (n ...

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in manageme...

Supportive measures and finer practice points in 177Lu-DOTATATE PRRT for NET: aiming for optimal disease management.

177Lu-DOTATATE based PRRT in patients of Metastatic Neuroendocrine tumor with single functioning kidney: Evaluation of tolerability and effect on Renal Function Parameters

Aims and Objectives: Assessment of renal toxicity profile of 177Lu-DOTATATE based Peptide Receptor Radionuclide therapy (PRRT) in patients of Metastatic Neuroendocrine tumor (NET) with a single functioning kidney. Materials and Methods: This was a retrospective analysis of NET patients, who had undergone PRRT with 177Lu-DOTATATE at a large tertiary care centre. The patients selected for the stu...

NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.

Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. Our study evaluated the potential radiosensitizing effects of inhibition of nicotineamide phosphoribosyltransferase on 177Lu-DOTATATE treatment in a NET model. METHODS Nude mice xenografted with ...